What 23 Analyst Ratings Have To Say About Eli Lilly and Co
Portfolio Pulse from Benzinga Insights
In the past three months, 23 analysts have provided ratings for Eli Lilly and Co (NYSE:LLY), showing a predominantly bullish outlook with an increase in the average 12-month price target to $833.91 from $728.79. The ratings reflect a mix of 'Buy', 'Overweight', and 'Neutral' stances, with significant price target adjustments by analysts from major firms. Eli Lilly's financial indicators such as revenue growth, net margin, and ROA are strong, although its ROE is below industry averages. The company's focus areas include neuroscience, cardiometabolic, cancer, and immunology.
May 01, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly has received a positive outlook from analysts, with an increased average price target suggesting confidence in its future performance. The company's strong financial health and strategic focus areas are likely to continue attracting investor interest.
The positive analyst ratings and increased price targets reflect a strong bullish sentiment towards Eli Lilly, indicating expectations of continued strong performance. The company's solid financial indicators, such as revenue growth and net margin, alongside its strategic focus on key healthcare areas, support this outlook. The unanimous bullish sentiment among analysts, coupled with the company's operational strengths, suggests a likely positive short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100